All News

All News2017-04-25T19:59:37+00:00

Windsor Expansion Helps BioVectra Meet Global Market Demand

Windsor Expansion Helps BioVectra Meet Global Market Demand

Extensive facility renovation, new equipment, assists life sciences firm in creating jobs, growing regional economy

April 12, 2018 – Windsor, NS – Atlantic Canada Opportunities Agency

Canada is a country of innovators. Curiosity, creativity and a collaborative spirit are what lead to the kinds of innovations and technologies that improve our daily lives and drive our economy, and our country, forward. That is why the Government of Canada is investing $5,000,000 in BioVectra Inc. to help the Charlottetown-based biotechnology and pharmaceutical ingredient manufacturing company expand its operations to Nova Scotia. This will enable the firm to grow, create additional highly skilled positions and help build sustained economic prosperity in Atlantic Canada.

The funding was announced today by the Honourable Scott Brison, Secretary of the Treasury Board and Member of Parliament for Kings-Hants, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA). The repayable contribution is being made through ACOA’s Business Development Program, which helps small and medium-sized enterprises expand and modernize to improve competitiveness.

BioVectra will use the assistance to complete major renovations at its Windsor facility and to purchase new equipment. This will allow the company to increase its capacity to develop and manufacture biologic drug substances for global pharmaceutical and biotechnology companies. These materials are used in the creation of products to treat cancer, autoimmune disorders, diabetes, arthritis, and many other serious illnesses.

The project will create 28 full-time positions, and by 2020, when the plant is fully operational, it is expected that more than double that number of people will be employed there.

This investment builds on commitments made by the Government of Canada and the four Atlantic Provinces to drive economic growth in the region through the Atlantic Growth Strategy, which supports strategic investments in initiatives that build on the region’s competitive advantages, such as its strong export potential, growing innovation network, and skilled workforce.

Follow ACOA on Twitter: @ACOACanada (


“Science and technology – along with stronger international trade – are rapidly changing the way Canadians live and work, bringing new challenges and more opportunities. Investing in BioVectra Inc., an industry-leading biotechnology and pharmaceutical ingredient manufacturing firm, will help strengthen and grow the middle class, and lay a more solid foundation for the next generations of Canadians.”

  • The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA

“The jobs of the future depend on Canadians’ ability to continue to adapt, innovate, and maintain our competitive edge in the fast-paced and increasingly global economy. BioVectra is already known worldwide for its expertise in developing and producing active pharmaceutical ingredients used in products that treat life-threatening diseases.

This modern, 50,000 square-foot facility will increase the company’s manufacturing capacity by 40 per cent and allow BioVectra to become a rare one-stop shop for its global biotech and pharmaceutical customers.”

  • The Honourable Scott Brison, President of the Treasury Board and Member of Parliament for Kings-Hants

“As an integral part and leader within the vibrant Atlantic Canadian BioScience cluster, we consider ourselves fortunate to operate in a supportive ecosystem where substantial emphasis is placed on talent, skills and innovation. The contribution from ACOA’s Business Development program will enable BioVectra to continue to thrive, create highly skilled jobs in Atlantic Canada, and help solidify Canadian leadership within the very competitive global markets we participate in.”

  • Oliver Technow, President, BioVectra Inc.

Quick Facts

  • BioVectra Inc., headquartered in Charlottetown, P.E.I., has more than 300 employees, and will initially add another 28 jobs in Windsor. The company’s four locations – three in Charlottetown and one in Windsor – total approximately 110,000 square feet.
  • BioVectra’s predecessor, Diagnostic Chemicals Ltd. (DCL), was founded in 1970 by Dr. Regis Duffy, then a UPEI chemistry professor, who began producing small amounts of a specialty chemical under contract to a U.S. firm.
  • Since its inception, BioVectra, which is part of the active pharmaceutical ingredient life cycle from early clinical development to commercial supply, has created hundreds of products used on the market today.


Alex Smith
Director of Communications and Outreach
Atlantic Canada Opportunities Agency
Phone: 902-426-9417 / 902-830-3839 (cell)

Jordan MacGregor
Communications and Marketing Manager
BioVectra Inc.
Phone: 902-566-9116 ext 6376

To watch a video of the event via Scott Brison, click here.

April 12th, 2018|News|

BioVectra wins BIOTECanada’s Gold Leaf Award for Company of the Year!


September 26, 2018 [OTTAWA] – BIOTECanada is pleased to announce the 2018 winners of the Gold Leaf Awards which annually highlight innovation and entrepreneurship within the Canadian biotechnology industry. This national celebration of the Canadian industry represents an outstanding collection of companies and individuals who have helped lead the industry throughout 2018.

“The remarkable individuals and companies we recognize through the Gold Leaf Awards are great examples of the core strengths of Canada’s biotech ecosystem including scientific excellence and passion,” commented Andrew Casey, President and CEO of BIOTECanada. “Importantly, Canada’s global biotech success is founded in its ability to advance scientific innovation by leveraging a diverse and vibrant ecosystem comprised of individuals, companies and institutions located in every province across the country. It is this strength that establishes Canada’s biotech industry as a leader in developing the solutions that will help address the global social and economic opportunities emerging from population growth and a changing climate.”

2018 BIOTECanada Gold Leaf Winners:

  • Aspect Biosystems Ltd. (Emerging Company of the Year)
  • BioVectra Inc. (Company of the Year)
  • CDRD – The Centre for Drug Research and Development (Ecosystem Builder)
  • Wilf Keller, CEO Ag-West Bio (Industry Leadership)

“To be selected as BIOTECanada’s Emerging Company of the Year, among so many notable biotech companies across the country, is a true honour,” said Tamer Mohamed, Aspect’s President and CEO. “We are inspired by the profound impact regenerative medicine therapies can have on patients around the globe and our team is committed to realizing this impact from right here in Canada.”

“On behalf of BioVectra, it is an honour to win BIOTECanada’s 2018 Gold Leaf Award for Biotech Company of the Year,” said Oliver Technow, President of BioVectra. “Our team has accomplished a lot over the past year. Our new biologics facility is now online in Windsor, Nova Scotia, we are making tremendous progress on an expansion at our headquarters in Charlottetown, Prince Edward Island, and we continue to build upon our capabilities, our development experience, and our technologies so that we can grow alongside our partners and help them advance their clinical programs efficiently. None of this would be possible without our highly dedicated and specialized employees. This award is truly a testament to their hard work and tenacity!”

“We are honoured that CDRD has been chosen to receive the BIOTECanada Gold Leaf Ecosystem Builder Award. This award is a testament to the tremendous dedication and hard work of each and every one of our team of 100+ scientists and business people; and the success they have achieved in commercializing innovation, attracting investment, supporting globally competitive Canadian companies; and helping generate long term, highly-skilled employment opportunities for Canadians – for moving us towards our Vision of being catalyst for Canada life sciences leading the world,” said Gordon C. McCauley, President and CEO of CDRD.

“It’s a great surprise and honour to receive the Gold Leaf Award from BioteCanada, an national entity that does the very important job coordinating and supporting biotech research. I’ve had the privilege of working with so many great people. It’s all about teamwork; I’ve been able to work with many excellent teams over the years. I look forward to continuing to contribute in any way I can.”

Global Biotech Week running September 24 – 30, 2018 brings together domestic and international biotechnology associations will experience hundreds of events across 20 countries. With thousands of participants each year, Global Biotech Week provides an opportunity to collaborate and showcase the impact biotechnology is having on economies celebrating science, innovation, and solutions.

September 26th, 2018|News|

Whitepaper: An Innovative Approach to Manufacturing Biologics Using Microbial Fermentation

Whitepaper: An Innovative Approach to Manufacturing Biologics Using Microbial Fermentation


The use of microbial fermentation to make biologics is growing rapidly. A manufacturing platform is an increasingly popular way to speed up process development stages and get a biologic to market faster. High-throughput systems can speed up optimization of each of these platform steps. Single-use, disposable technologies are starting to replace stainless steel to streamline biologic manufacturing, reduce costs, minimize contamination risks and allow rapid expansion of capacity.

Key Learning Objectives

  • What a platform technology is and how it can speed up process development.
  • How high-throughput technologies can be used in biologic process development.
  • What single-use, disposable technologies are currently on the market for biologics manufacturing and the advantages of using them.

Brought to you by

BioVectra logo

Please complete the form to download the whitepaper.
Please select all that apply.
Please select all that apply.
August 1st, 2018|Articles|

BioVectra and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins

BioVectra and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins

16/07/18 – CHARLOTTETOWN, Prince Edward Island, Canada – Today, BioVectra Inc., a global Contract Development and Manufacturing Organization (CDMO) with microbial fermentation and synthesis capabilities with high containment, and TUBE Biopharmaceuticals GmbH, an Austrian biotech company active in the research field of cytotoxic payloads, announced that they have signed an exclusive license agreement for microbial fermentation technology to manufacture tubulysins.

After conducting further development, optimization and upscaling of the strain initially developed by TUBE Biopharmaceuticals, BioVectra intends to provide the marketplace with research- and cGMP-grade tubulysins and downstream derivatives.

Tubulysins belong to a cytotoxic tetrapeptidic natural product class that result in disruption of microtubule networks and inhibition of tubulin polymerization of cancer cells, and are suitable for use in conjugation approaches such as Antibody Drug Conjugates (ADCs), specifically targeting drug-resistant cancers.

Financial details of this unlimited agreement were not disclosed.

For more information, please contact Jordan MacGregor, at

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit

About TUBE Biopharmaceuticals

TUBE Pharmaceuticals GmbH ( was founded in January 2011 in Austria having its labs in Vienna. TUBE Pharmaceuticals develops and commercializes drug candidates derived from natural products with high potency for novel therapeutic applications in the field of oncology. Together with advanced targeting approaches safer and more efficacious therapies especially preventing tumor resistance are to be expected for patients. In-licensing opportunities in the field of natural products derived oncology drugs closer to the clinics complement the internally developed assets of the Company and help to transform the Company into an oncology development company with an attractive pipeline to create further value.

July 16th, 2018|News, Uncategorised|

BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion

CHARLOTTETOWN, Prince Edward Island (12/14/2017) – BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease.

BioVectra Inc. brings over 45 years of contract development and manufacturing experience to the partnership, including working with Keryx to manufacture Ferric Citrate API since 2003. BioVectra will prepare for the anticipated growth in the long-term Ferric Citrate API supply needs by expanding production capacity at their headquarters facility in Charlottetown, PEI, Canada.

“This partnership is a pivotal step in our journey as BioVectra. It is a shining example of the innovation, talent and determination we have cultivated in the Atlantic Canada region. We take great pride in serving the needs of global partners and the patients they are treating,” said BioVectra President, Oliver Technow. “We are very pleased to bring an agreement of this magnitude, creating highly skilled jobs, to Charlottetown, PEI. It is another terrific accomplishment for bioscience in Atlantic Canada.”

“With the recent U.S. FDA approval of Auryxia for a second indication, it is critical that we have sufficient manufacturing capacity to support anticipated future prescription demand,” said Melissa Bradford-Klug, Chief Business Officer of Keryx Biopharmaceuticals. “BioVectra has been manufacturing the active pharmaceutical ingredient in Auryxia since 2003 and we believe they will be a great partner as we continue to expand the supply chain for Auryxia.”

“This partnership illustrates what BioVectra does best. Since Keryx first approached us for clinical supply nearly 15 years ago,  we have collaborated on Auryxia’s clinical phases, registration, and commercial launch to a point where we are expanding capacity to meet increased market demand,” said Vice President of Business Development, Heather Delage. “We look forward to continuing to be an important part of Keryx’s long-term strategic supply chain.”

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets. For more information about Keryx, please visit

About BioVectra

BioVectra is a CDMO that serves pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • GMP Microbial Fermentation & Purification
  • Complex Chemistry
  • Process & Analytical Development

For more information about BioVectra, please visit

Media Contact

Jordan MacGregor
Marketing and Communications Manager
902-566-9116 ext. 6376

December 14th, 2017|Articles, News|

BioVectra Inc. Celebrates the Opening of Flagship Warehouse & Process Development Suites as part of Global Biotech Week

Charlottetown, Prince Edward Island (September 21, 2017) – BioVectra Inc. is proud to announce the opening of a new flagship warehouse and process development suites in Charlottetown, Prince Edward Island.

“A vibrant and successful BioScience cluster holds one of the keys to continued growth and prosperity for Canada,” BioVectra’s President Oliver Technow said. “BioVectra is well positioned as a leader in the highly competitive market we participate in, capitalizing on our unique capabilities, 300 tremendously skilled employees and unwavering commitment to quality.”

“The recent and future investments demonstrate our ability to remain competitive and to be at the global forefront of innovation and success, right here in Atlantic Canada,” Technow continued. “Our new, state-of-the-art warehouse meets our business needs of today and the future, exemplifying our dedication to grow further.”

“BioVectra is an excellent example of a company that is constantly adapting to the ever changing technological and scientific landscape in the bioscience industry,” Economic Development and Tourism Minister Heath MacDonald said. “It is a leader in an industry that is growing rapidly, adding new, highly skilled jobs, and gaining an international reputation for our province.”

BioVectra’s grand opening coincides with Global Biotech Week, a Canadian initiative that originated in 2003 to raise awareness of the industry and its global potential.

“Global Biotech Week provides an important opportunity to recognize and celebrate biotechnology innovation and the role it plays in addressing environmental and health challenges,” President and CEO of BIOTECanada Andrew Casey said. “Canada is one of a number of nations that are home to thriving and diverse biotechnology ecosystems which are developing game changing and life altering innovations.”

BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the biotechnology sector.

“BioVectra’s 45 year history, recent growth in Windsor, Nova Scotia and today’s addition of new warehouse and process development suites in Charlottetown, Prince Edward Island is a great example of a made in Canada globally competitive company,” Casey added. “The Canadian biotech ecosystem is supported by strong clusters in every province across the country offering Canadians competitive highly skilled 21st century jobs. All combined, the ecosystem is a strategic economic asset for Canada within the emerging global bio-economy.”

The new 21,000 square foot warehouse enhances BioVectra’s ability to grow with the global demand for its products and services. Equipped with 400 pallet positions, the new warehouse also provides the opportunity to grow with built-in expansions.

“As our business continues to grow, so does the need for storage of our raw materials, consumables and finished products,” BioVectra’s Planning and Operations Manager Tim Murphy said.

With a total investment of $4M, the new warehouse is equipped with a devoted loading dock, dedicated sampling rooms, robust security system and tight temperature controls to keep products at their required temperatures.

About BioVectra

BioVectra is a CDMO that serves pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable partner with a strong quality history, BioVectra has over 45 years of experience specializing in:

  • Microbial Fermentation
  • Complex Chemistry
  • High Potency APIs
  • Process & Analytical Development
  • Drug Development

Media Contact

Jordan MacGregor
Marketing and Communications Manager
902-566-9116 ext. 6376

September 21st, 2017|Articles, News|

BioVectra Inc. to Open New Microbial Fermentation and Complex Chemistry Site in December 2017

$30 million investment increases BioVectra’s total manufacturing capacity by 40%

WINDSOR, Nova Scotia – BioVectra Inc., a Contract Development and Manufacturing Organization (CDMO) providing cGMP services to globally operated biotech and pharmaceutical companies, today announced that its fourth cGMP facility will be fully operational by December 2017. The late-stage to commercial-scale microbial fermentation and complex chemistry facility is located in Windsor, Nova Scotia, with proximity and service to Northeast USA development entities.

BioVectra’s $30 million investment has equipped the 50,000 square-foot facility with 40,000 liters (L) of fermentation capacity, downstream processing equipment and new pre-clinical fermentation and potent chemistry suites. “The investment strengthens our unique position in the very competitive global marketplace, enabling us to offer new and existing clients range of scale throughout the entire lifecycle of a product,” said Oliver Technow, BioVectra’s President.

The new facility is an investment in BioVectra’s core development and manufacturing competencies: microbial fermentation and complex chemistries. As an industry leader in microbial fermentation of both small and large molecules, the company provides scalable cGMP operations from 30 L to 17,000 L. BioVectra has the capability to handle the development and cGMP scale-up of high-potency active pharmaceutical ingredients (APIs), handling potent substances such as antibody-drug conjugate warheads, with occupational exposure limit (OEL) levels of < 20 ng/m3 (Safebridge Band 3 and 4).

The new facility increases BioVectra’s ability to partner with global pharmaceutical companies by offering dual-site risk mitigation. “This expansion helps BioVectra keep up with the growing demand for our products, while also meeting an underserved need for large-scale microbial fermentation in North America,” said Heather Delage, Vice President of Business Development. “In addition to the facility’s large-scale fermentation capability, the site also offers a complementary footprint for synthetic process development and laboratory-based activities.”

BioVectra’s three additional cGMP facilities and headquarters are located in Charlottetown, Prince Edward Island.

Media Contact 
Jordan MacGregor, 902-566-9116 ext. 6376
Communications Manager

May 24th, 2017|Articles|

Join us in New York City for DCAT Week 2017 – March 20-23

March 6, 2017

Join us in New York City for DCAT Week 2017 – March 20-23

Join us in New York City for DCAT Week 2017 on March 20-23, 2017. DCAT Week is the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries. It is organized and hosted by the Drug, Chemical & Associated Technologies Association (DCAT) to assist its member companies with their business development objectives. The event’s unique model brings together members for high-level strategic meetings with key decision makers, timely educational programs and important networking opportunities.

March 6th, 2017|News|

DCAT Announces New Advisory Council Member

November 1, 2016


DCAT Announces New Advisory Council Member

Robbinsville, NJ, November 1, 2016 – The Drug, Chemical & Associated Technology Association (DCAT) is pleased to announce that Oliver Technow, president of BioVectra, Inc., has been elected by the membership to serve on DCAT’s Advisory Council for a three-year term beginning November 1, 2016.

“We look forward to Mr. Technow’s contributions to the DCAT organization,” said Executive Director Margaret Timony. “He brings valuable industry experience and leadership skills that will help shape and support the organization’s programs, events and projects.”

More information on new DCAT Leadership can be found here.

About DCAT
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing. With over 400 corporate members, DCAT is headquartered in Robbinsville, New Jersey.

March 5th, 2017|News|

BioVectra Goes Global

Some 45 years ago, Regis Duffy saw large-scale opportunity in the pharmaceutical and diagnostic marketplace and created the origins of BioVectra Inc. in a Charlottetown garage. In the ensuing decades, BioVectra has earned global recognition and a key role in Atlantic Canada’s bioscience sector.

View Article

February 26th, 2017|Articles|

Joint Venture Contract Services – A CDMO’S Approach To Being A True Partner

September 20, 2016

Joint Venture Contract Services – A CDMO’S Approach To Being A True Partner

The active pharmaceutical ingredient (API) is the key functional component of a pharmaceutical formulation, rendering efficacy to the final drug product. Driven by the aging population, public and government demands for affordable drugs, reimbursement pressure and expansion of the emerging market, the pharmaceutical market is expanding rapidly. With this, the global market for APIs will rise steadily, meeting the increased need for medicines across the board. The market is expected to reach $198.8 billion by 2022, growing from $121.4 billion in 2014 at a compound annual growth rate (CAGR) of 6.4%.

View Article

September 20th, 2016|Articles|

What makes BioVectra a “Leader in today’s competitive CDMO market.”

June 8, 2016

What makes BioVectra a “Leader in today’s competitive CDMO market.”

BioVectra’s new President Oliver Technow shares his insight story about what makes BioVectra a “Leader in today’s competitive CDMO market.”  BioVectra started its journey more than 45 years ago as a fine chemical and enzyme producer for the pharmaceutical and diagnostic industries. Today, with four facilities and roughly 300 employees in Eastern Canada, BioVectra is focused on partnering in innovative ways in the long-term manufacturing and development of APIs and drug substances.

View Article

June 8th, 2016|Articles|